Breaking News, Collaborations & Alliances

Seattle Genetics, Millennium in Lymphoma Alliance

Seattle Genetics and Millennium have entered into a development and commercialization agreement for lymphoma treatment brentuximab vedotin.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Seattle Genetics and Millennium: The Takeda Oncology Company have entered into an agreement to globally develop and commercialize brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeting CD30. SGN-35 is in late-stage trials for the treatment of relapsed and refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). Seattle Genetics will receive an upfront payment of $60 million and retains full commercialization rights for brentuximab vedotin in the U...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters